---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021051"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:55:03.445104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ardelyx Q2 net loss narrows to $26.9M; IBSRELA sales start at $1.6M

## Summary
- Net product sales of IBSRELA were $1.6M in Q2 2022, first commercial quarter post-launch.
- Net loss $26.9M ($0.19/share) vs $45.2M ($0.45) in Q2 2021; cash & investments $81.0M.
- Entered $20M financing with HealthCare Royalty based on future royalties from Kyowa Kirin.
- FDA advisory committee for XPHOZAH NDA tentatively scheduled for Nov 16, 2022.
- Survey data: 41% of GIs report using IBSRELA; 92% rate it as a substantial/moderate advance.

## SEC filing metadata
- accession: 0001628280-22-021051
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/0001628280-22-021051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/ardx-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021051
- JSON: https://secwatch.observer/filing/0001628280-22-021051.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.